Variables | Univariate | Multivariate | ||
---|---|---|---|---|
HR (95% CI) | p | HR (95% CI) | p | |
Age, yrs | 0.99 (0.98–1.02) | 0.904 | 1.01 (0.99–1.04) | 0.334 |
Male | 0.79 (0.40–1.58) | 0.506 | 0.67 (0.33–1.35) | 0.264 |
Socioeconomic status | ||||
Intermediate income | 1.00, Reference | Reference | ||
Low income | 0.98 (0.64–1.48) | 0.907 | ||
Serum creatinine at presentation, per mg/dl | 0.62 (0.45–0.85) | 0.002 | 0.83 (0.59–1.17) | 0.287 |
Proteinuria at presentation, per g/g | 0.92 (0.86–0.99) | 0.017 | 0.91 (0.84–0.98) | 0.013 |
Interstitial fibrosis, per % unit | 0.98 (0.97–0.99) | 0.010 | ||
Tubular atrophy, per % unit | 0.98 (0.97–0.99) | 0.004 | ||
Activity score, per unit | 1.04 (0.99–1.09) | 0.101 | ||
Chronicity score, per unit | 0.87 (0.79–0.96) | 0.004 | 0.90 (0.81–1.01) | 0.068 |
No vascular lesions | 2.25 (1.44–3.52) | < 0.001 | 2.05 (1.25–3.37) | 0.004 |
Induction regimen | ||||
IVC | 1.00, Reference | Reference | 1.00, Reference | Reference |
MMF | 1.88 (1.18–3.00) | 0.008 | 2.04 (1.25–3.33) | 0.005 |
AZA | 0.87 (0.47–1.61) | 0.667 | 0.64 (0.34–1.21) | 0.166 |
MMF: mycophenolate mofetil; IVC: intravenous cyclophosphamide; AZA: azathioprine.